Systemic psoriasis biomarkers differentially impact clinical responses to deucravacitinib and apremilast in moderate-to-severe plaque psoriasis: Insight from phase 3 studies

Journal of Investigative Dermatology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles